UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-02, Vol.24 (2), p.314-321

2013

Volltextzugriff (PDF)

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-09, Vol.24 (9), p.2390-2396

2013

Volltextzugriff (PDF)

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Annals of oncology, 2015-11, Vol.26 (11), p.2267-2274

2015

Volltextzugriff (PDF)

Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis

Cardiovascular research, 2015-07, Vol.107 (1), p.32-44

2015

Volltextzugriff (PDF)

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel

British journal of cancer, 2015-06, Vol.113 (1), p.20-29

2015

Volltextzugriff (PDF)

Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S21-S21

2014

Volltextzugriff (PDF)

[18 F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) + gemcitabine (gem) for metastatic pancreatic cancer (MPC)

European journal of cancer (1990), 2016-12, Vol.69, p.S118-S118

2016

Volltextzugriff (PDF)

Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases

Journal of clinical oncology, 2001-04, Vol.19 (7), p.2074-2083

2001

Volltextzugriff (PDF)

Cost Effectiveness of Nab-Paclitaxel Plus Carboplatin (nab-PC) Relative to Bevacizumab Plus Solvent-Based Paclitaxel and Carboplatin (B+sb-PC) in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S61-S62

2014

Volltextzugriff (PDF)

In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer

International journal of radiation oncology, biology, physics, 1999-11, Vol.45 (4), p.981-989

1999

Volltextzugriff (PDF)

A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging

Clinical cancer research, 1999-04, Vol.5 (4), p.739-745

1999

Volltextzugriff (PDF)

Long-term Follow-up of Patients Treated on Phase I Trial of Conformal Radiotherapy followed by Gamma Knife Boost with Concurrent Motexafin Gadolinium

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S279-S280

2011

Volltextzugriff (PDF)

Primary Histology is Associated with Volumetric Response Following Whole Brain Radiation Therapy (WBRT) in Patients with Brain Metastases (BM)

International journal of radiation oncology, biology, physics, 2008, Vol.72 (1), p.S207-S207

2008

Volltextzugriff (PDF)

The emerging role of reactive oxygen species in cancer therapy

European journal of cancer (1990), 2004-09, Vol.40 (13), p.1934-1940

Renschler, Markus F

2004

Volltextzugriff (PDF)

358 - [18F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) + gemcitabine (gem) for metastatic pancreatic cancer (MPC)

European journal of cancer (1990), 2016-12, Vol.69, p.S118-S118

2016

Volltextzugriff (PDF)

Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): Locally Advanced Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S21-S21

2014

Volltextzugriff (PDF)

Photoangioplasty for human peripheral atherosclerosis: Results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin)

Circulation (New York, N.Y.), 2000-11, Vol.102 (19), p.2322-2324

2000

Volltextzugriff (PDF)

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.7000-7000

2011

Volltextzugriff (PDF)

Synthetic Peptide Ligands of the Antigen Binding Receptor Induce Programmed Cell Death in a Human B-Cell Lymphoma

Proceedings of the National Academy of Sciences - PNAS, 1994-04, Vol.91 (9), p.3623-3627

1994

Volltextzugriff (PDF)

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial

Journal of clinical oncology, 2004-01, Vol.22 (1), p.157-165

2004

Volltextzugriff (PDF)

Cost Effectiveness of Nab-Paclitaxel Plus Carboplatin (nab-PC) Relative to Bevacizumab Plus Solvent-Based Paclitaxel and Carboplatin (B+sb-PC) in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC): Outcomes/Health Services Research

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S61-S62

2014

Volltextzugriff (PDF)

Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases

Journal of clinical oncology, 2003-07, Vol.21 (13), p.2529-2536

2003

Volltextzugriff (PDF)

9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial

European journal of cancer supplements, 2009, Vol.7 (2), p.540-541

2009

Volltextzugriff (PDF)

9121 Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial

European journal of cancer supplements, 2009, Vol.7 (2), p.541-541

2009

Volltextzugriff (PDF)

B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification

Cancer research (Chicago, Ill.), 1995-12, Vol.55 (23), p.5642-5647

1995

Volltextzugriff (PDF)

1 – 25 von 214

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(135)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(134)
Physical Sciences
(83)
Technology
(67)
Materials Science
(57)
Materials Science, Multidisciplinary
(56)
Life Sciences & Biomedicine
(50)
Humans
(38)
Physics
(36)
Materials Science, Coatings & Films
(30)
Physics, Condensed Matter
(30)
Chemistry
(27)
Chemistry, Multidisciplinary
(26)
Female
(18)
Male
(18)
Biological And Medical Sciences
(17)
Oncology
(17)
Earth Sciences
(16)
Exact Sciences And Technology
(16)
Geology
(16)
Geosciences, Multidisciplinary
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel

Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

[18 F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) + gemcitabine (gem) for metastatic pancreatic cancer (MPC)

Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases

Cost Effectiveness of Nab-Paclitaxel Plus Carboplatin (nab-PC) Relative to Bevacizumab Plus Solvent-Based Paclitaxel and Carboplatin (B+sb-PC) in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer

A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging

Long-term Follow-up of Patients Treated on Phase I Trial of Conformal Radiotherapy followed by Gamma Knife Boost with Concurrent Motexafin Gadolinium

Primary Histology is Associated with Volumetric Response Following Whole Brain Radiation Therapy (WBRT) in Patients with Brain Metastases (BM)

The emerging role of reactive oxygen species in cancer therapy

358 - [18F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) + gemcitabine (gem) for metastatic pancreatic cancer (MPC)

Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): Locally Advanced Non-Small Cell Lung Cancer

Photoangioplasty for human peripheral atherosclerosis: Results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin)

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC)

Synthetic Peptide Ligands of the Antigen Binding Receptor Induce Programmed Cell Death in a Human B-Cell Lymphoma

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial

Cost Effectiveness of Nab-Paclitaxel Plus Carboplatin (nab-PC) Relative to Bevacizumab Plus Solvent-Based Paclitaxel and Carboplatin (B+sb-PC) in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC): Outcomes/Health Services Research

Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases

9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial

9121 Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial

B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification

Suchergebnisse filtern